Learn the underside half of this put up for a historical past of Hope Medication and Bayer’s HMI-115. This remedy targets the prolactin (PRL) receptor to treatment hair loss. Hope Medication raised $56 million in funding final yr. Their pipeline web page is value monitoring.
The preliminary cause for all this pleasure was because of the spectacular long-lasting hair development outcomes seen in stump-tailed macaque monkeys. Per the scientific trial participant I point out additional under, these monkeys are nonetheless being monitored and haven’t misplaced their hair over 4 years after prolactin receptor antibody remedy.
Replace: November 16, 2022 — A November 2, 2022 detailed Reddit replace from a trial participant in Australia is required studying. This 37-year outdated man had his first two doses (in a single month) of the prolactin blocker through injection. He, alongside along with his feminine companion (age 46) will get remedy each two weeks for six months. So a complete of 12 doses, all at Sinclair Dermatology in Melbourne. Observe that whereas these are Part 1 trials in Australia, the identical HMI-115 product is scheduled to endure Part 2 scientific trials within the US anytime quickly.
This Redddit person moeman32 appears utterly respectable and has been on Reddit for over ten years. He has additionally posted about Australia many occasions prior to now. All of us owe him main respect. He’ll do follow-up posts each two weeks. Observe that each one 20 sufferers on this Part 1 security trial are getting the precise drug (i.e., no placebo wanted to check efficacy this time round).
“The vortex current hair has crammed out a lot thicker and faster. The frontal scalp is now rising dormant hair. The hairline has positively moved 15mm ahead and the hair is a couple of cm lengthy (havent had a haircut since earlier than the trial). All in all, it’s making a visual distinction to my hairline.”
Replace: June 22, 2022 — Hope Medication’s web site is now working. Because of reader “Pinotq” for letting us know. See their analysis part and pipeline pages.
Replace: April 12, 2022 — For some cause, Australian Part 1 trials for Hope Medication’s HMI-115 are beginning right this moment. They’ll contain 20 individuals and are anticipated to be accomplished in July 2023. The trials can be led by the famend hair loss skilled Dr. Rodney Sinclair. Additionally see his present scientific trials recruiting web page hair part.
Replace: April 14, 2022 — A lot of pleasure on Reddit.
In the meantime, US Part 2 trials ought to begin at any second now (learn additional under). This distinction in trial development by nation could be very unusual. Maybe is has to do with some stricter Australian authorities necessities.
Replace: January 26, 2022
Hope Medication HMI-115 Part 2 Trials
Hope Medication simply acquired FDA approval to begin Part 2 scientific trials within the US for its HMI-115 product to deal with androgenetic alopecia. HMI-115 is a human monoclonal antibody drug that targets the PRL receptor for the remedy of female and male sample hair loss. Final yr, the US FDA additionally accepted Part 2 trials of the identical drug to deal with endometriosis.
The Part II scientific trial of HMI-115 for the remedy of androgenetic alopecia:
“Will probably be a world multi-center, randomized, double-blind, placebo-controlled research. It is going to be carried out in the USA, Australia and different international locations.”
Replace: November 28, 2021
New CEO Henri Doods Interview
A reader despatched me the under screenshot of Hope Medication CEO Henri Doods’ Chinese language journal interview that I discussed earlier. If anybody can translate into English, please put up within the feedback. Click on on the picture to increase.
Replace: September 20, 2021
Reader “Karl” simply notified us that there’s a model new cowl web page interview of Hope Medication’s CEO Dr. Henri Doods in a Chinese language journal “tradetree.cn”. If anybody can acquire entry to it (see right here) and translate into English, please strive. Not value buying as but in my view.
Per Karl, Part 2 scientific trials for hair loss product HMI-115 are deliberate for This autumn 2021 (however no proof anyplace else). This matches what we anticipated per the prior updates that I mentioned in Could (see additional under). Observe that HMI-115 is similar as Bayer’s prolactin receptor antibody. Hope Medication has the rights to the event of this product.
Could 9, 2021
Hope Medication (China) Raises $56 Million
Till now, Kintor Pharmaceutical (China) was the principle cause for latest pleasure. Nonetheless, this weekend, the individuals on this web site’s hair loss chat are discussing Hope Medication. Out of the blue, this startup firm acquired $56 million in a Collection B spherical of financing. Funding companies Qiming Enterprise Companions and Grand Flight Funding led the way in which.
Different buyers embody: HighLight Capital; Sinovation Ventures (a enterprise capital agency led by former Google China head Kai-Fu Lee); and Trustbridge. Extra right here.
HMI-115 PRL Receptor Concentrating on: Bayer License
“Beforehand, HopeMed signed an unique license settlement with Bayer AG on the event and commercialization of a human antibody (HMI-115) concentrating on the prolactin (PRL) receptor for the remedy of female and male sample hair loss. At current, HMI-115 has accomplished part I scientific trials within the European Union, with optimistic security outcomes. The worldwide multi-center part II scientific trials for androgenic alopecia and can quickly be launched.“
Observe that I first coated Hope Medication in my 2019 put up on its partnership with Bayer regarding the prolactin receptor. The corporate was based by Dr. Rui-Ping Xiao, the dean of the Faculty of Future Know-how of Peking College. Apparently, she can also be an affiliate editor of the New England Journal of Medication. Replace: See this web page for rather more on Dr. Xiao Ruiping.
Essentially the most uncommon a part of this story is that Hope Medication’s official web site (hopemedinc.com) has not labored for weeks. I’ve e-mailed a number of of their workers, and can replace this put up if I get any response.
